226 related articles for article (PubMed ID: 24156018)
1. Inhibition of MMP14 potentiates the therapeutic effect of temozolomide and radiation in gliomas.
Ulasov I; Thaci B; Sarvaiya P; Yi R; Guo D; Auffinger B; Pytel P; Zhang L; Kim CK; Borovjagin A; Dey M; Han Y; Baryshnikov AY; Lesniak MS
Cancer Med; 2013 Aug; 2(4):457-67. PubMed ID: 24156018
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of elongation factor-2 kinase augments the antitumor activity of Temozolomide against glioma.
Liu XY; Zhang L; Wu J; Zhou L; Ren YJ; Yang WQ; Ming ZJ; Chen B; Wang J; Zhang Y; Yang JM
PLoS One; 2013; 8(11):e81345. PubMed ID: 24303044
[TBL] [Abstract][Full Text] [Related]
3. Silencing erythropoietin receptor on glioma cells reinforces efficacy of temozolomide and X-rays through senescence and mitotic catastrophe.
Pérès EA; Gérault AN; Valable S; Roussel S; Toutain J; Divoux D; Guillamo JS; Sanson M; Bernaudin M; Petit E
Oncotarget; 2015 Feb; 6(4):2101-19. PubMed ID: 25544764
[TBL] [Abstract][Full Text] [Related]
4. Knockdown of RLIP76 expression by RNA interference inhibits invasion, induces cell cycle arrest, and increases chemosensitivity to the anticancer drug temozolomide in glioma cells.
Wang Q; Qian J; Wang J; Luo C; Chen J; Hu G; Lu Y
J Neurooncol; 2013 Mar; 112(1):73-82. PubMed ID: 23292182
[TBL] [Abstract][Full Text] [Related]
5. Local delivery of slow-releasing temozolomide microspheres inhibits intracranial xenograft glioma growth.
Dong J; Zhou G; Tang D; Chen Y; Cui B; Dai X; Zhang J; Lan Q; Huang Q
J Cancer Res Clin Oncol; 2012 Dec; 138(12):2079-84. PubMed ID: 22825126
[TBL] [Abstract][Full Text] [Related]
6. Can hsp90alpha-targeted siRNA combined with TMZ be a future therapy for glioma?
Cruickshanks N; Shervington L; Patel R; Munje C; Thakkar D; Shervington A
Cancer Invest; 2010 Jul; 28(6):608-14. PubMed ID: 20210521
[TBL] [Abstract][Full Text] [Related]
7. Knockdown of SLC34A2 inhibits cell proliferation, metastasis, and elevates chemosensitivity in glioma.
Bao Z; Chen L; Guo S
J Cell Biochem; 2019 Jun; 120(6):10205-10214. PubMed ID: 30592329
[TBL] [Abstract][Full Text] [Related]
8. Aplysin enhances temozolomide sensitivity in glioma cells by increasing miR-181 level.
Gong A; Ge N; Yao W; Lu L; Liang H
Cancer Chemother Pharmacol; 2014 Sep; 74(3):531-8. PubMed ID: 25047724
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of DNA-repair genes Ercc1 and Mgmt enhances temozolomide efficacy in gliomas treatment: a pre-clinical study.
Boccard SG; Marand SV; Geraci S; Pycroft L; Berger FR; Pelletier LA
Oncotarget; 2015 Oct; 6(30):29456-68. PubMed ID: 26336131
[TBL] [Abstract][Full Text] [Related]
10. Downregulation of BRCA1-BRCA2-containing complex subunit 3 sensitizes glioma cells to temozolomide.
Chai KM; Wang CY; Liaw HJ; Fang KM; Yang CS; Tzeng SF
Oncotarget; 2014 Nov; 5(21):10901-15. PubMed ID: 25337721
[TBL] [Abstract][Full Text] [Related]
11. Bortezomib inhibits growth and sensitizes glioma to temozolomide (TMZ) via down-regulating the FOXM1-Survivin axis.
Tang JH; Yang L; Chen JX; Li QR; Zhu LR; Xu QF; Huang GH; Zhang ZX; Xiang Y; Du L; Zhou Z; Lv SQ
Cancer Commun (Lond); 2019 Dec; 39(1):81. PubMed ID: 31796105
[TBL] [Abstract][Full Text] [Related]
12. Effect of IFN-beta on human glioma cell lines with temozolomide resistance.
Yoshino A; Ogino A; Yachi K; Ohta T; Fukushima T; Watanabe T; Katayama Y; Okamoto Y; Naruse N; Sano E
Int J Oncol; 2009 Jul; 35(1):139-48. PubMed ID: 19513561
[TBL] [Abstract][Full Text] [Related]
13. Combination of anti-VEGF therapy and temozolomide in two experimental human glioma models.
Grossman R; Brastianos H; Blakeley JO; Mangraviti A; Lal B; Zadnik P; Hwang L; Wicks RT; Goodwin RC; Brem H; Tyler B
J Neurooncol; 2014 Jan; 116(1):59-65. PubMed ID: 24185441
[TBL] [Abstract][Full Text] [Related]
14. Integrin αVβ3 silencing sensitizes malignant glioma cells to temozolomide by suppression of homologous recombination repair.
Christmann M; Diesler K; Majhen D; Steigerwald C; Berte N; Freund H; Stojanović N; Kaina B; Osmak M; Ambriović-Ristov A; Tomicic MT
Oncotarget; 2017 Apr; 8(17):27754-27771. PubMed ID: 27487141
[TBL] [Abstract][Full Text] [Related]
15. MT1-MMP silencing by an shRNA-armed glioma-targeted conditionally replicative adenovirus (CRAd) improves its anti-glioma efficacy in vitro and in vivo.
Ulasov I; Borovjagin AV; Kaverina N; Schroeder B; Shah N; Lin B; Baryshnikov A; Cobbs C
Cancer Lett; 2015 Sep; 365(2):240-50. PubMed ID: 26052095
[TBL] [Abstract][Full Text] [Related]
16. Enhanced cytotoxic effect of radiation and temozolomide in malignant glioma cells: targeting PI3K-AKT-mTOR signaling, HSP90 and histone deacetylases.
Choi EJ; Cho BJ; Lee DJ; Hwang YH; Chun SH; Kim HH; Kim IA
BMC Cancer; 2014 Jan; 14():17. PubMed ID: 24418474
[TBL] [Abstract][Full Text] [Related]
17. Upregulation of CASC2 sensitized glioma to temozolomide cytotoxicity through autophagy inhibition by sponging miR-193a-5p and regulating mTOR expression.
Jiang C; Shen F; Du J; Fang X; Li X; Su J; Wang X; Huang X; Liu Z
Biomed Pharmacother; 2018 Jan; 97():844-850. PubMed ID: 29136760
[TBL] [Abstract][Full Text] [Related]
18. MiR-143 acts as a tumor suppressor by targeting N-RAS and enhances temozolomide-induced apoptosis in glioma.
Wang L; Shi ZM; Jiang CF; Liu X; Chen QD; Qian X; Li DM; Ge X; Wang XF; Liu LZ; You YP; Liu N; Jiang BH
Oncotarget; 2014 Jul; 5(14):5416-27. PubMed ID: 24980823
[TBL] [Abstract][Full Text] [Related]
19. DNMT1 mediates chemosensitivity by reducing methylation of miRNA-20a promoter in glioma cells.
Zhou D; Wan Y; Xie D; Wang Y; Wei J; Yan Q; Lu P; Mo L; Xie J; Yang S; Qi X
Exp Mol Med; 2015 Sep; 47(9):e182. PubMed ID: 26337869
[TBL] [Abstract][Full Text] [Related]
20. Up-regulation of miR-497 confers resistance to temozolomide in human glioma cells by targeting mTOR/Bcl-2.
Zhu D; Tu M; Zeng B; Cai L; Zheng W; Su Z; Yu Z
Cancer Med; 2017 Feb; 6(2):452-462. PubMed ID: 28064447
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
